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TRANSLATING EVIDENCE INTO IMPACT
ICA Foundation Supports LNG IUS Access in Low- and Middle-
Income Countries 
INTRODUCTION
The Population Council began developing Mirena® in 
the late 1970s1 with the aim of creating a contraceptive 
device combining the beneficial features of both 
hormonal contraceptives and intrauterine devices. 
Mirena®, approved by the Food and Drug Administration 
in 2000 and added to the World Health Organization’s 
Essential Medicines list in 2015, provides up to six years 
of safe, effective, and continuous contraception for 
women.  
Mirena®, produced in Finland by Bayer, is distributed 
in the private market and is available in more than 
120 countries. “LNG IUS” is the version of the product 
distributed in the public sector ouside the United 
States. However,  Mirena® and other branded long-
acting reversible contraceptive (LARC) products remain 
prohibitively expensive2 for many users. Service delivery 
and demand constraints have also hindered large-scale 
public sector introductions of the method.  
The Council remains committed to continuing to 
improve access to the LNG IUS and other reproductive 
health products serving women and men in LMICs. 
The Population Council has developed and introduced several of the world’s most effective 
and popular contraceptive methods, including the levonorgestrel-releasing intrauterine 
system (LNG IUS). Through the International Contraceptive Access (ICA) Foundation, a 
public-private foundation based in Finland, the Council supports LNG IUS distribution 
to women in over 35 low- and middle-income countries (LMICs) in partnership with 
international and local organizations. Over 150,000 LNG IUS units have been delivered 
to date at no cost, laying the groundwork for method introduction in LMICs and further 
expanding access to safe, long-acting, reversible contraception.
In 2004, the Population Council and Bayer AG joined 
forces to establish the ICA Foundation, a public-private 
partnership, as a creative way of enhancing access to 
this innovative product. The Foundation, through its 
network of partners across multiple countries, has been 
engaged in serving women’s needs for expanded long-
acting reversible contraceptive options. The Council 
holds two ex-officio board seats on the Foundation and 
three positions on the Secretariat that manages the 
Foundation’s affairs. 
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RESEARCH SUMMARY 
The Council’s development of the LNG IUS/Mirena® 
with Bayer Oy (formerly Leiras Oy) sought to 
improve available intrauterine devices with the aim of 
decreasing menstrual bleeding and preventing anemia 
with the addition of a progestin (levonorgestrel, hence 
the generic name). The commercially marketed 
Mirena® was approved by the FDA for contraception in 
2000 and later for the treatment of heavy menstrual 
bleeding. The LNG IUS is available on a not-for-profit 
basis through donations by the ICA Foundation to 
service delivery organizations working in low-resource 
settings. 
The LNG IUS has numerous benefits:3 up to six 
years of protection, a pregnancy rate of less than 1 
percent in the first year of use, a strong safety record 
comparable to sterilization, rapid return to fertility 
after removal, the ability to lighten menstrual bleeding 
and cramping, and the potential reduction in iron-
deficiency anemia. Clinical data is available for over 
13,000 women-years of product use, demonstrating 
high efficacy and acceptance.  
RESEARCH USE AND IMPACT  
The Council plays a unique role by employing 
a “bench to bedside” approach,4 investing in 
contraceptive development from early laboratory 
research to product introduction. To expand 
contraceptive options and provide access to the LNG 
IUS across varied settings, the Population Council and 
Bayer AG, through the ICA Foundation, have provided 
the unbranded LNG IUS on a not-for-profit basis for 
over 15 years. 
To date, the ICA Foundation has donated over 
150,000 LNG IUS devices5 to organizations in 37 
LMICs, helping to prevent thousands of unintended 
pregnancies, unsafe abortions, and maternal 
deaths.6 These donations support the work of 
governments and local not-for-profit organizations, 
hospitals, and global partners that share the 
Council’s commitment to improving access to quality 
family planning services and expanding modern 
contraceptive options.  
Across multiple contexts, ICA Foundation 
donations have responded to growing demand 
for modern contraception, expanded access to 
LARCs, and laid the groundwork for LNG IUS 
introduction in multiple LMICs. In several countries, 
such as Kenya, Nigeria, and Zambia, donated LNG 
IUS units have supported demonstration projects 
that provided a foundation for broader access to the 
method, institutionalization within national health 
systems, opportunities for regional replication and 
encouraging new manufacturing options. 
The ICA Foundation has responded to growing 
demand for LARCs by supporting efforts to expand 
access to the LNG IUS through the public sector 
in multiple countries. In Kenya, recent LNG IUS 
donations contributed to a Jhpiego-coordinated 
initiative7 to build capacity for increasing access to 
modern contraception, including LARCs, through 
public-sector facilities in Kisumu and Migori 
counties. In partnership with the Ministry of Health, 
the LNG IUS was added to the modern contraceptive 
options offered at select high-volume facilities. 
Through these collaborative efforts, the LNG IUS 
is now included in Kenya’s national family planning 
training curriculum and health information systems. 
In addition, efforts are underway to transition 
management of commodity donations from Jhpiego 
to the Government of Kenya. 
Modest donations of LNG IUS product have been 
catalytic in setting the stage for sustained efforts to 
increase access to the method within existing health 
systems by energizing service delivery organizations, 
harnessing the reach of professional associations, 
and creating linkages between public and private 
stakeholders. In Nigeria, LNG IUS donations have 
supported the efforts of Rotary and several local 
partners promoting provider skills-building activities; 
community outreach involving men and religious 
leaders; and increased availability of modern 
contraceptives, including LARCs, across multiple 
states. The ICA Foundation, in collaboration with 
these partners and others, has also contributed 
to recent efforts by Nigeria’s Federal Ministry of 
Health to sustain and expand access to hormonal 
IUS through a national plan for coordinated and 
phased introduction within the country’s health 
system.  
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LOOKING FORWARD
The ICA Foundation will continue to support 
increased LNG IUS availability in LMICs through its 
donation program. Beyond sustained country-level 
donations, the Foundation also continues to shape 
global markets, demonstrating the demand for long-
acting methods, fostering competition, ensuring 
a more reliable and greater volume of supply, and 
stimulating more favorable pricing. In addition, USAID 
and UNFPA are in the process of adding the hormonal 
IUS to their procurement catalogs so that interested 
international buyers can procure the product.
For more information, please visit the  
ICA Foundation.
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